Health Care • Biotechnology: Pharmaceutical Preparations
$17.41 ▼ -1.59
(-8.37%)
MKT CAP: $278.9M • VOL: 174.7K
52W L $8 52W H $34
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
GLSI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$19.4M | -$17.6M | -$9.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$19.4M | -$17.4M | -$8.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.9M | -$7.3M | -$6.5M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$9.9M | -$7.3M | -$6.5M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.2M | $4.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $353.2K | $908.6K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GLSI.